Cann Group adds A$2M to private credit facility to retire convertible notes

What's the deal? Cann GroupDealroom has a profile for this one. Try Dealroom → has secured a A$2 million increase to its existing private credit loan facility, less establishment fees, on the same terms as the current arrangement. The Australian medicinal cannabis company can only draw the funds for approved purposes, including early redemption of its convertible notes.

Why now? The increase follows earlier guidance that Cann was in talks with its debt provider about securing more funding. It arrives as the company restructures its debt and retires convertible notes, part of its ongoing capital management strategy.

What's the endgame? Cann develops, produces, and supplies cannabis medicines from a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. It offers dried flower, oil, vape, and edible products under its Botanitech and Mallee Bloom brands, plus bulk and white-label supplies. The added funding is meant to strengthen financial flexibility as it scales operations.

What could go wrong? The company's market capitalisation stands at just A$7.47 million, and its shares fell 11.11% on the update. Facilities of this kind can carry double-digit interest rates and fee-heavy structures, adding to the cost of the raise.

The signal: The quick re-raise fits a broader pattern of cannabis operators leaning on structured debt and private credit amid a tight equity and public-market environment. In North America, operators such as Tilt HoldingsDealroom has a profile for this one. Try Dealroom → have turned to senior secured notes and private financiers, underscoring a sector-wide shift toward non-bank credit. At A$2 million, Cann's move is a tactical funding step rather than a transformative one.